Merkel Cell Carcinoma - Pipeline Review, H1 2020

June 2020 | 535 pages | ID: MD91E31DE2CEN
Global Markets Direct

Abstracts

Merkel Cell Carcinoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2020, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 28, 14, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.
Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Merkel Cell Carcinoma - Overview
Merkel Cell Carcinoma - Therapeutics Development
Merkel Cell Carcinoma - Therapeutics Assessment
Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
Merkel Cell Carcinoma - Drug Profiles
Merkel Cell Carcinoma - Dormant Projects
Merkel Cell Carcinoma - Discontinued Products
Merkel Cell Carcinoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Merkel Cell Carcinoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Merkel Cell Carcinoma - Pipeline by 4SC AG, H1 2020
Merkel Cell Carcinoma - Pipeline by Amgen Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Apcure SAS, H1 2020
Merkel Cell Carcinoma - Pipeline by Arcus Biosciences Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2020
Merkel Cell Carcinoma - Pipeline by BeiGene Ltd, H1 2020
Merkel Cell Carcinoma - Pipeline by bluebird bio Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Boston Biomedical Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2020
Merkel Cell Carcinoma - Pipeline by Checkpoint Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020
Merkel Cell Carcinoma - Pipeline by CytomX Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Dragonfly Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Dormant Projects, H1 2020
Merkel Cell Carcinoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Merkel Cell Carcinoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG
Amgen Inc
Apcure SAS
Arcus Biosciences Inc
Bavarian Nordic A/S
BeiGene Ltd
bluebird bio Inc
Boston Biomedical Inc
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Dragonfly Therapeutics Inc
Eli Lilly and Co
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Genexine Inc
Harbin Gloria Pharmaceuticals Co Ltd
ImmunityBio Inc
Immunomic Therapeutics Inc
Incyte Corp
Kartos Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Morphogenesis Inc
NantKwest Inc
Nektar Therapeutics
NextCure Inc
Novartis AG
Ocellaris Pharma Inc
OncoSec Medical Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
QBiotics Ltd
Replimune Ltd
RHEACELL GmbH & Co KG
Sotio AS
Spring Bank Pharmaceuticals Inc
Tarveda Therapeutics Inc